 Justin Honce
Concepts (146)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Magnetic Resonance Imaging | 15 | 2023 | 3039 | 1.100 |
Why?
| | Multiple Sclerosis | 4 | 2021 | 380 | 0.830 |
Why?
| | Immunologic Factors | 2 | 2019 | 220 | 0.680 |
Why?
| | Glatiramer Acetate | 1 | 2019 | 20 | 0.640 |
Why?
| | Psychotherapy | 1 | 2020 | 149 | 0.630 |
Why?
| | Rituximab | 1 | 2019 | 150 | 0.600 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 1 | 2019 | 69 | 0.600 |
Why?
| | Epilepsy | 2 | 2017 | 277 | 0.500 |
Why?
| | Neuroimaging | 1 | 2016 | 249 | 0.450 |
Why?
| | Meningeal Neoplasms | 3 | 2021 | 87 | 0.370 |
Why?
| | Cochlear Implantation | 2 | 2023 | 80 | 0.340 |
Why?
| | Natalizumab | 2 | 2021 | 46 | 0.340 |
Why?
| | Cochlear Implants | 2 | 2023 | 94 | 0.330 |
Why?
| | Meningioma | 2 | 2021 | 77 | 0.330 |
Why?
| | Brain Concussion | 1 | 2016 | 472 | 0.320 |
Why?
| | Central Nervous System | 2 | 2021 | 237 | 0.300 |
Why?
| | Pyrazoles | 3 | 2021 | 364 | 0.280 |
Why?
| | Pyrimidines | 2 | 2021 | 378 | 0.280 |
Why?
| | Brain | 4 | 2021 | 2374 | 0.280 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 3 | 2021 | 973 | 0.270 |
Why?
| | Pyridines | 2 | 2021 | 425 | 0.250 |
Why?
| | Middle Aged | 14 | 2022 | 26757 | 0.200 |
Why?
| | Central Nervous System Diseases | 1 | 2023 | 61 | 0.200 |
Why?
| | Lung Neoplasms | 3 | 2021 | 2199 | 0.200 |
Why?
| | Parkinson Disease | 2 | 2017 | 345 | 0.190 |
Why?
| | Intracranial Aneurysm | 1 | 2022 | 91 | 0.190 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2021 | 25 | 0.190 |
Why?
| | Atrophy | 1 | 2021 | 152 | 0.180 |
Why?
| | Hypnosis | 1 | 2020 | 9 | 0.180 |
Why?
| | Relaxation Therapy | 1 | 2020 | 15 | 0.180 |
Why?
| | Humans | 25 | 2023 | 114757 | 0.180 |
Why?
| | Radiology, Interventional | 1 | 2020 | 26 | 0.170 |
Why?
| | Radiology Department, Hospital | 1 | 2019 | 15 | 0.170 |
Why?
| | Skull Base Neoplasms | 1 | 2019 | 24 | 0.160 |
Why?
| | Antineoplastic Agents | 2 | 2021 | 1895 | 0.160 |
Why?
| | Maintenance Chemotherapy | 1 | 2019 | 22 | 0.160 |
Why?
| | Induction Chemotherapy | 1 | 2019 | 56 | 0.160 |
Why?
| | Cerebral Arterial Diseases | 1 | 2019 | 42 | 0.160 |
Why?
| | Adult | 11 | 2022 | 30548 | 0.160 |
Why?
| | Neurologic Examination | 1 | 2019 | 114 | 0.160 |
Why?
| | Lactams, Macrocyclic | 1 | 2018 | 46 | 0.160 |
Why?
| | Blepharospasm | 1 | 2018 | 7 | 0.160 |
Why?
| | Torticollis | 1 | 2018 | 12 | 0.150 |
Why?
| | Demyelinating Diseases | 1 | 2019 | 75 | 0.150 |
Why?
| | Basal Ganglia | 1 | 2018 | 44 | 0.150 |
Why?
| | Organophosphorus Compounds | 1 | 2018 | 72 | 0.150 |
Why?
| | Posterior Leukoencephalopathy Syndrome | 1 | 2018 | 9 | 0.150 |
Why?
| | Brain Neoplasms | 2 | 2016 | 984 | 0.150 |
Why?
| | Fingolimod Hydrochloride | 1 | 2018 | 29 | 0.150 |
Why?
| | Sinus Thrombosis, Intracranial | 1 | 2017 | 21 | 0.140 |
Why?
| | Epilepsy, Temporal Lobe | 1 | 2017 | 20 | 0.140 |
Why?
| | Disability Evaluation | 1 | 2019 | 271 | 0.140 |
Why?
| | Academic Medical Centers | 1 | 2019 | 413 | 0.140 |
Why?
| | Spin Labels | 1 | 2016 | 44 | 0.140 |
Why?
| | Cerebellum | 1 | 2018 | 200 | 0.130 |
Why?
| | Surgery, Computer-Assisted | 1 | 2017 | 62 | 0.130 |
Why?
| | Laser Therapy | 1 | 2017 | 100 | 0.130 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2016 | 76 | 0.130 |
Why?
| | Medical Marijuana | 1 | 2017 | 97 | 0.130 |
Why?
| | Brain Ischemia | 1 | 2019 | 299 | 0.130 |
Why?
| | Gray Matter | 1 | 2015 | 67 | 0.120 |
Why?
| | Immunosuppressive Agents | 1 | 2019 | 647 | 0.120 |
Why?
| | Gene Rearrangement | 1 | 2015 | 138 | 0.120 |
Why?
| | Double-Blind Method | 1 | 2019 | 1662 | 0.120 |
Why?
| | Neurosurgical Procedures | 1 | 2016 | 152 | 0.120 |
Why?
| | Cerebrovascular Circulation | 1 | 2016 | 220 | 0.120 |
Why?
| | Mitochondrial Diseases | 1 | 2015 | 77 | 0.120 |
Why?
| | Anxiety | 1 | 2020 | 842 | 0.110 |
Why?
| | Health Services Accessibility | 1 | 2019 | 763 | 0.110 |
Why?
| | Nucleus Accumbens | 1 | 2015 | 124 | 0.110 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2015 | 227 | 0.110 |
Why?
| | Endovascular Procedures | 1 | 2017 | 268 | 0.110 |
Why?
| | Glioma | 1 | 2016 | 294 | 0.110 |
Why?
| | Male | 13 | 2023 | 55579 | 0.100 |
Why?
| | Female | 13 | 2022 | 59507 | 0.100 |
Why?
| | Quality Improvement | 1 | 2019 | 951 | 0.100 |
Why?
| | Contrast Media | 3 | 2021 | 343 | 0.100 |
Why?
| | Brain Injuries | 1 | 2016 | 452 | 0.090 |
Why?
| | Young Adult | 3 | 2021 | 10463 | 0.090 |
Why?
| | Cannabis | 1 | 2017 | 384 | 0.090 |
Why?
| | Diagnosis, Differential | 1 | 2015 | 1340 | 0.090 |
Why?
| | Artifacts | 2 | 2023 | 113 | 0.090 |
Why?
| | Hippocampus | 1 | 2015 | 695 | 0.090 |
Why?
| | Quality of Life | 1 | 2021 | 2358 | 0.090 |
Why?
| | Stroke | 1 | 2019 | 1019 | 0.090 |
Why?
| | Retrospective Studies | 6 | 2022 | 12515 | 0.080 |
Why?
| | Aged | 7 | 2022 | 19094 | 0.080 |
Why?
| | Sensitivity and Specificity | 2 | 2022 | 1691 | 0.070 |
Why?
| | Substance-Related Disorders | 1 | 2015 | 947 | 0.070 |
Why?
| | Adolescent | 2 | 2021 | 17808 | 0.060 |
Why?
| | Monkeypox virus | 1 | 2023 | 12 | 0.050 |
Why?
| | Angiography, Digital Subtraction | 1 | 2022 | 43 | 0.050 |
Why?
| | Cerebral Angiography | 1 | 2022 | 109 | 0.050 |
Why?
| | Computed Tomography Angiography | 1 | 2022 | 97 | 0.050 |
Why?
| | Disease Progression | 2 | 2019 | 2387 | 0.050 |
Why?
| | Artificial Intelligence | 1 | 2022 | 145 | 0.050 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2023 | 473 | 0.050 |
Why?
| | Treatment Outcome | 3 | 2018 | 9089 | 0.040 |
Why?
| | Hospital Bed Capacity, 500 and over | 1 | 2019 | 3 | 0.040 |
Why?
| | Time Management | 1 | 2019 | 18 | 0.040 |
Why?
| | Magnets | 1 | 2019 | 15 | 0.040 |
Why?
| | Prognosis | 2 | 2019 | 3334 | 0.040 |
Why?
| | Appointments and Schedules | 1 | 2019 | 73 | 0.040 |
Why?
| | Transportation of Patients | 1 | 2019 | 52 | 0.040 |
Why?
| | Lactams | 1 | 2018 | 18 | 0.040 |
Why?
| | Efficiency, Organizational | 1 | 2019 | 126 | 0.040 |
Why?
| | Drug Approval | 1 | 2018 | 78 | 0.040 |
Why?
| | Aminopyridines | 1 | 2018 | 81 | 0.040 |
Why?
| | Tomography Scanners, X-Ray Computed | 1 | 2018 | 17 | 0.040 |
Why?
| | Databases, Bibliographic | 1 | 2018 | 29 | 0.040 |
Why?
| | Diffusion Tensor Imaging | 1 | 2018 | 62 | 0.040 |
Why?
| | Gadolinium | 1 | 2018 | 73 | 0.040 |
Why?
| | Dura Mater | 1 | 2017 | 27 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2019 | 6350 | 0.040 |
Why?
| | Lymphoma, B-Cell | 1 | 2018 | 86 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2018 | 528 | 0.030 |
Why?
| | Mood Disorders | 1 | 2017 | 112 | 0.030 |
Why?
| | Radiosurgery | 1 | 2019 | 302 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2019 | 268 | 0.030 |
Why?
| | Memory Disorders | 1 | 2017 | 155 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2018 | 718 | 0.030 |
Why?
| | Inpatients | 1 | 2019 | 378 | 0.030 |
Why?
| | Recurrence | 1 | 2018 | 936 | 0.030 |
Why?
| | Memory | 1 | 2017 | 211 | 0.030 |
Why?
| | Fatigue | 1 | 2017 | 295 | 0.030 |
Why?
| | Disabled Persons | 1 | 2017 | 132 | 0.030 |
Why?
| | Affect | 1 | 2017 | 246 | 0.030 |
Why?
| | Length of Stay | 1 | 2019 | 949 | 0.030 |
Why?
| | Limbic System | 1 | 2015 | 43 | 0.030 |
Why?
| | Survival Analysis | 1 | 2018 | 1218 | 0.030 |
Why?
| | Tremor | 1 | 2015 | 45 | 0.030 |
Why?
| | Gait Disorders, Neurologic | 1 | 2015 | 41 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 1122 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 1796 | 0.030 |
Why?
| | Marijuana Smoking | 1 | 2017 | 224 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 1 | 2022 | 2269 | 0.030 |
Why?
| | Anticoagulants | 1 | 2017 | 547 | 0.030 |
Why?
| | Internet | 1 | 2017 | 596 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2019 | 2763 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2539 | 0.020 |
Why?
| | Sex Factors | 1 | 2015 | 1717 | 0.020 |
Why?
| | Colorado | 1 | 2019 | 4086 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 4420 | 0.020 |
Why?
| | Time Factors | 1 | 2018 | 6124 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2017 | 4625 | 0.020 |
Why?
| | Obesity | 1 | 2017 | 2513 | 0.020 |
Why?
|
|
Honce's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|